- The United Kingdom is introducing significant updates to its clinical trial regulations through the adoption of the International Council for Harmonisation (ICH) E6 (R3) Good Clinical Practice (GCP) guideline. The updated framework modernizes clinical trial oversight and aligns UK requirements with internationally recognized standards.
- ICH E6 (R3) GCP consists of the GCP principles, two annexes, appendices A, B and C, and a glossary. The UK government confirmed that the principles outlined in ICH E6 GCP will replace the current UK GCP principles, which were primarily based on older EU legislation.
- From 28 April 2026, compliance with the ICH E6 (R3) GCP Principles — as amended from time to time — will become a legal requirement in the UK under Regulation 28 of the amended UK Clinical Trials Regulations. The regulation states that no person may conduct a clinical trial or perform sponsor functions except in accordance with the principles and conditions of GCP.
- The updated regulation also clarifies that sponsor responsibilities include:
- Development and maintenance of trial-specific computerized systems;
- Oversight of laboratories analyzing human samples;
- Conduct and management of clinical trials.
- The UK has also retained several country-specific GCP principles under the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025. These include:
- Compliance with the Declaration of Helsinki;
- Insurance requirements for clinical trials;
- A requirement for sponsors and investigators to consider all relevant guidance when conducting clinical trials.
- Importantly, while only the ICH E6 GCP principles are legally binding, the annexes remain highly relevant guidance and cannot be ignored. Sponsors and investigators are expected to give due regard to the annexes when designing and conducting studies.
- The guidance also highlights a flexible and risk-proportionate approach, stating that:
- “Clinical trial processes, measures and approaches should be implemented in a way that is proportionate to the risks to participants and to the importance of the data collected and that avoids unnecessary burden on participants and investigators.”
- Sponsors are expected to review ICH E6 (R3) principles and Annex 1 and make any necessary updates to their quality management systems to ensure compliance before April 2026.
- The revised framework aims to improve flexibility, innovation, participant protection, and data reliability across UK clinical research.
May 11, 2026
